Dimeric Bisbenzimidazole DB 2 A(7) Protects Mice From Lethal Genital Herpes and Herpetic Skin Lesions
Journal of Medical Virology · 2026
DOI: 10.1002/jmv.70758 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Virology, 2026. Verfasst von Natalia A Demidova und 9 weiteren Autor:innen. Beteiligte Einrichtung: Gamaleya National Research Centre for Epidemiology and Microbiology, Ministry of Health of the Russian Federation, Moscow, Russia. Hauptthemen laut MEDLINE: Herpes Genitalis, Antiviral Agents, Herpesvirus 1, Human, Benzimidazoles. Die Arbeit nennt 31 Literaturangaben.
Abstract (Originalsprache)
Herpes simplex virus type 1 (HSV‐1) is among the most common pathogens in the human population. Primary infection and reactivation of the virus can cause serious diseases and death. The drug resistance to all approved anti‐HSV agents poses a significant challenge, especially for immunocompromised patients. This study focuses on some details of the dimeric bisbenzimidazole DB 2 A(7) synthesis and its antiviral properties of against both HSV‐1 sensitive and resistant acyclovir isolates. Optimization of the synthesis of DB 2 A(7) resulted in an increase in the total yield from 20% to 44%, reduction of labor intensity and removal of highly toxic and carcinogenic hydrazine. The DB 2 A(7) binding to thymus DNA was confirmed by a combination of physicochemical methods including calculation of the binding constant. DB 2 A(7) demonstrated the in vitro capacity to inhibit viral activity, both before and after cell infection, and effectively inactivated cell‐free viruses. Gene expression analysis by RT‐PCR revealed a significant reduction in the transcription of the gene encoding the immediate early ICP0 HSV‐1 protein, suggesting a mechanism of action different from that of acyclovir. We first demonstrated the in vivo preventive effect of DB 2 A(7) towards lethal skin HSV‐1 infection in mice as well as its capacity to protect animals from lethal genital herpes. The data obtained implied the potential of the synthesized DB 2 A(7) as a new antiviral agent against the lethal HSV‐1 infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gamaleya National Research Centre for Epidemiology and Microbiology, Ministry of Health of the Russian Federation, Moscow, Russia.
- Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia.
- Emanuel Institute of Biochemical Physics, Russian Academy of Sciences, Moscow, Russia.
ORCID-Profile: Natalia A Demidova, Regina R Klimova, Albert F Arutyunyan
Zitieren
APA
Demidova, N. A., Klimova, R. R., Arutyunyan, A. F., Koval, V. S., Kostyukov, A. A., Kuzmin, V. A., Shubina, E. A., Simonov, R. A., Zhuze, A. L., & Kushch, A. A. (2026). Dimeric Bisbenzimidazole DB 2 A(7) Protects Mice From Lethal Genital Herpes and Herpetic Skin Lesions. Journal of Medical Virology. https://doi.org/10.1002/jmv.70758
Vancouver
Demidova NA, Klimova RR, Arutyunyan AF, Koval VS, Kostyukov AA, Kuzmin VA, et al. Dimeric Bisbenzimidazole DB 2 A(7) Protects Mice From Lethal Genital Herpes and Herpetic Skin Lesions. Journal of Medical Virology. 2026. doi:10.1002/jmv.70758
BibTeX
@article{Demidova2026,
author = {Demidova, Natalia A and Klimova, Regina R and Arutyunyan, Albert F and Koval, Vasiliy S and Kostyukov, Alexey A and Kuzmin, Vladimir A and Shubina, Elena A and Simonov, Ruslan A and Zhuze, Alexei L and Kushch, Alla A},
title = {Dimeric Bisbenzimidazole DB 2 A(7) Protects Mice From Lethal Genital Herpes and Herpetic Skin Lesions},
journal = {Journal of Medical Virology},
year = {2026},
doi = {10.1002/jmv.70758}
}
EUVIMED